# Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

> **NCT03970746** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **PDC*line Pharma SAS** · enrollment: 73 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** PDC*lung01
- **DRUG:** Keytruda Injectable Product
- **DRUG:** Alimta Injectable Product

## Key facts

- **NCT ID:** NCT03970746
- **Lead sponsor:** PDC*line Pharma SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-10
- **Primary completion:** 2024-07-18
- **Final completion:** 2025-12
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03970746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03970746, "Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03970746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*